Shelonitda Rose has joined Advaxis, a biotechnology company developing cancer immunotherapries based in Princeton, NJ, US, as Vice President, Clinical Development.
Most recently Director of Oncology Research at Merck & Co, Rose brings to Advaxis more than 15 years of experience in medical oncology and haematology clinical research.
In her new role, Rose will oversee clinical development programmes for the company's Lm Technology platform.
The company has initiated three new clinical trials in 2015, including a combination study involving ADXS-PSA and Merck's PD-1 checkpoint inhibitor Keytruda (pembrolizumab). The company also expects to initiate six additional clinical trials by the end of the year to evaluate its Lm Technology immunotherapy in cervical cancer, HPV-associated anal cancer and HER2 expressing solid tumours.
Prior to joining Merck, Rose was the Programme Director for the Haematology-Oncology Fellowship Programme and an Associate Professor of Medicine and of Pathology and Transfusion Medicine at the University of Medicine and Dentistry of New Jersey (UMDNJ) - Robert Wood Johnson Medical School from 2002 to 2010, and Assistant Professor of Medicine in the Division of Haematology/Oncology at The Texas A&M University Health Science Centre Medical School from 2000 to 2002.